These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36806299)

  • 1. Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
    Yalamanchali A; Yang K; Roof L; Lopetegui-Lia N; Schwartzman LM; Campbell SR; Woody NM; Silver N; Koyfman S; Geiger JL; Yilmaz E
    Head Neck; 2023 Apr; 45(4):862-871. PubMed ID: 36806299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
    Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
    BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Scheff NN; Nilsen ML; Li J; Harris AL; Acharya R; Swartz A; Hsieh RW; Anderson JL; Ferris RL; Menk AV; Delgoffe GM; Zandberg DP
    Oral Oncol; 2023 May; 140():106363. PubMed ID: 36963232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Hernando-Calvo A; Mirallas O; Marmolejo D; Saavedra O; Vieito M; Assaf Pastrana JD; Aguilar S; Bescós C; Lorente J; Giralt J; Benavente S; Temprana-Salvador J; Alberola M; Dienstmann R; Garralda E; Felip E; Villacampa G; Brana I
    Oral Oncol; 2023 May; 140():106364. PubMed ID: 36989964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
    Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Okada T; Matsuki T; Fushimi C; Okamoto I; Sato H; Kondo T; Tokashiki K; Ito T; Masubuchi T; Tada Y; Miura K; Hanyu K; Omura GO; Takahashi H; Yamashita T; Oridate N; Tsukahara K
    Anticancer Res; 2022 Oct; 42(10):4907-4912. PubMed ID: 36192003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
    Lau A; Yang WF; Li KY; Su YX
    Crit Rev Oncol Hematol; 2020 Sep; 153():102984. PubMed ID: 32569853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
    Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
    Fukuda N; Yunokawa M; Fujiwara Y; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1322. PubMed ID: 33295110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
    Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.
    Zhang X; Wang P; Chai Y; Zhou X; Li P; Wang X
    Am J Otolaryngol; 2024; 45(1):104065. PubMed ID: 37879241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study.
    Konuthula N; Do OA; Gobillot T; Rodriguez CP; Futran ND; Houlton J; Barber BR
    Head Neck; 2022 Nov; 44(11):2465-2472. PubMed ID: 35930296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
    Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
    Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.